Dr. Costa on the Promising Role of CAR T-Cell Therapy in Multiple Myeloma

Video

Luciano J. Costa, MD, PhD, discusses the promising role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Luciano J. Costa, MD, PhD, an associate professor of medicine in the Blood and Marrow Transplantation and Cell Therapy Program at the University of Alabama’s Birmingham School of Medicine, discusses the promising role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

As in other hematologic malignancies, such as acute lymphoblastic leukemia and non-Hodgkin lymphoma, CAR T-cell therapy has been shown to be a highly potent therapeutic modality among patients with relapsed/refractory multiple myeloma, says Costa.

Moreover, most patients with myeloma who received investigational CAR T-cell therapy were refractory to proteasome inhibitors, immunomodulatory agents, and CD38-directed monoclonal antibodies, Costa explains.

Although responses tend to occur quickly and persist for several months, it does not seem likely at this point that patients with multiple myeloma will derive long-term responses with CAR T-cell therapy as has been observed in some patients with lymphoma and leukemia, Costa says.

However, patients with relapsed/refractory multiple myeloma tend to derive responses that require little monitoring, suggesting this will be a well-tolerated treatment in the future, concludes Costa.

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.